1CM
MXCT icon

1492 Capital Management’s MaxCyte MXCT Stock Holding History

1492 Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,321
Closed -$74.9K – 103
2023
Q2 		$74.9K Hold
16,321
– – 0.04% 98
2023
Q1 		$80.8K Buy
+16,321
New +$80.4K 0.05% 98

Other funds holding MXCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1492 Capital Management's MXCT Position: Q3 2023 in Review

1492 Capital Management sold out of MaxCyte (MXCT) in Q3 2023, closing a stake of 16,321 shares — an estimated $74.9K sold.

1492 Capital Management first reported a position in MXCT in Q1 2023 and held it in 2 quarters. The position peaked at $80.8K in Q1 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2023.

  • 1492 Capital Management reported no remaining MaxCyte position as of Q3 2023 after selling out during the quarter.
  • 1492 Capital Management sold 16,321 MaxCyte shares in Q3 2023, an estimated $74.9K.
  • 1492 Capital Management first reported a position in MaxCyte in Q1 2023 and held it in 2 quarters.
  • 1492 Capital Management's MaxCyte position peaked at $80.8K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2023.

Based on 1492 Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.